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The transcription of neuron-specific genes must be repressed in
nonneuronal cells. RESTNRSF is a transcription factor that restricts
the expression of many neuronal genes through interaction with
the neuron-restrictive silencer element at the promoter level.
PAHX-AP1 is a neuronal gene that is developmentally up-regulated
in the adult mouse brain but that has no functional NRSE motif in
its 5 upstream sequence. Here, we report that the transcription
factor AP4 and the corepressor geminin form a functional complex
in which SMRT and histone deacetylase 3 are recruited. The
functional complex represses PAHX-AP1 expression in nonneuro-
nal cells and participates in regulating the developmental expres-
sion of PAHX-AP1 in the brain. This complex also serves as a
transcriptional repressor of DYRK1A, a candidate gene for Down’s
syndrome. Furthermore, compared with that in normal fetal brain,
the expression of AP4 and geminin is reduced in Down’s syndrome
fetal brain at 20 weeks of gestation age, at which time premature
overexpression of dual-specificity tyrosine-phosphorylated and
regulated kinase 1A (DYRK1A) is observed. Our findings indicate
that AP4 and geminin act as a previously undescribed repressor
complex distinct from RESTNRSF to negatively regulate the ex-
pression of target genes in nonneuronal cells and suggest that the
AP4–geminin complex may contribute to suppressing the preco-
cious expression of target genes in fetal brain.
The expression of neuronal genes in neural tissues is regulated byactivator and repressor systems that provide the proper tran-
scriptional pattern (1, 2). One of these systems, interaction of the
neuron-restrictive silencer element (NRSE) with repressor element
1-silencing transcription factor (REST, also known as neuron-
restrictive silencer factor or NRSF), mediates the repression of
several neuronal genes in nonneuronal cells, such as type II sodium
channel, SCG10, and synapsin I.RESTacts on promoters that carry
the NRSE sequence to repress transcription, which is thought to be
a general mechanism for the control of neuron-specific gene
expression (3–5). However, the transcriptional regulatory mecha-
nisms required to direct the temporal expression of brain-specific
genes are not fully understood.
Phytanoyl-CoA -hydroxylase-associated protein 1 (PAHX-
AP1) was isolated as a novel neuron-specific protein that interacts
withRefsumdisease gene product (PAHX) (6) and the cytoplasmic
region of brain-specific angiogenesis inhibitor 1, a seven-span
transmembrane protein (7). Refsum disease is an autosomal reces-
sive disorder of lipid metabolism; retinitis pigmentosa and periph-
eral neuropathy are major clinical findings (8). PAHX-AP1 is
involved in the developmental regulation of the photoreceptor’s
function (9) and is weakly expressed in most embryonic tissues, but
its expression pattern changes dramatically after birth when it is
specifically expressed in the brain in a developmentally up-
regulated pattern (6). Studies in transgenic (TG) mice showed that
the 5-kb region of 5 PAHX-AP1 gene is sufficient to direct the
developmental expression of a reporter gene in the brain only,
especially neuronal cells, in a pattern similar to that of endogenous
PAHX-AP1 (10), which indicates that the 5-kb region contains the
sequences required to direct temporal brain-specific expression in
vivo. However, no functional NRSEmotif was found within 5 kb of
the PAHX-AP1 promoter (Fig. 7, which is published as supporting
information on the PNAS web site), which indicates that elements
distinct from the NRSE must be present for neuron-specific tran-
scriptional up-regulation of PAHX-AP1 in the adult brain.
Identification of NRSE-like sequences that repress transcription
and binding repressor proteins is important because these se-
quences may represent common regulatory elements involved in
the transcriptional control of other neuronal genes. In this regard,
the PAHX-AP1 gene can provide an attractive model for revealing
other NRSE-like sequences. Previously, we identified a putative
repressive element (PRE) in the PAHX-AP1 promoter sequence
that is suspected to be required for directing brain-specific expres-
sion (10), and we hypothesized that PRE-binding proteins may
participate in the negative regulation of PAHX-AP1 expression in
brain at the promoter level.
In the present study, we screened for PRE-binding proteins to
elucidate the responsible molecular mechanisms and potential
implications of this PRE-binding transcription factor in the regu-
latory control of brain-specific gene expression. Here, we report
that activator protein 4 (AP4) is a PRE-binding transcription factor
and thatAP4 and the corepressor geminin (Gem) formapreviously
uncharacterized functional complex to repress target gene expres-
sion in nonneuronal cells. The AP4–Gem complex may provide a
second mechanism for silencing neuronal genes in nonneuronal
cells that operates in parallel to the previously reported REST
neuron-restrictive silencer factor (NRSF).
Results
AP4 Is a Transcriptional Repressor of PAHX-AP1, and Gem Interacts
with AP4 to Form a Complex. To search for PRE-binding proteins,
we used the yeast one-hybrid assay and obtained several positive
clones, two of which simultaneously expressed the transcription
factor AP4 and Gem; the others contained AP4 only. AP4 is a
ubiquitously expressed transcription factor that binds to the DNA
consensus sequence 5-CAGCTG-3 and ahelix–loop–helix protein
that contains two distinctive leucine-repeat elements, LR1 andLR2
(11). Gem is a bifunctional protein that acts in embryonic neural-
ization (12) and in replication licensing in the cell cycle (13). We
found that in vitro translated AP4-V5 (Fig. 1A Left) or native AP4
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in nuclear extract (Fig. 8, which is published as supporting infor-
mation on the PNASweb site) binds specifically toWTPAHX-AP1
PRE but not to mutant PRE oligonucleotide (Fig. 1A Right).
Unexpectedly, however, Gemdid not bind to the PRE (Fig. 1A and
8) but interacted with AP4 (Fig. 1B). Binding of endogenous AP4
to the AP4-binding site on PAHX-AP1 promoter sequence was
confirmed by ChIP (Fig. 1C). The positive result of the ChIP assay
with anti-Gem antibody indicated that AP4 and Gem form a
complex. In HEK293T cells, cotransfection of AP4 dose-
dependently repressed the luciferase activity of the PAHX-AP1
promoter reporter, whereas site-directed mutation of the AP4
binding site resulted in a loss of repression by AP4 (Fig. 1D).
The transcription factors function cooperatively by forming large
complexes with one another at their promoter sequences. Protein–
protein interactions between DNA-binding transcription factors
and non-DNA-binding factors have been shown to be responsible
for the transcriptional regulation of gene expression (14, 15).
Although no evidence suggests that Gem binds to promoter DNA
directly, it is possible that Gem interacts with transcription factors
or other proteins to alter their activity. AP4 contains multiple
protein–protein interfaces that function to promote homodimer
formation and restrict heterocomplexes (14). Although Gem’s
neuralizing activity is localized to an N-terminal domain, a C-
terminal domain contains the predicted coiled-coil region that
inhibits the initiation of DNA replication (12). We thus prepared
various AP4 and Gem deletion constructs to map the interacting
domain (Figs. 9 A and B, which is published as supporting infor-
mation on the PNAS web site) and found that the C-terminal
domain of Gem binds to the LR1- and LR2-containing region of
AP4 (Fig. 1 E and F).
AP4–Gem Functional Complex Works as a Transcriptional Repressor of
PAHX-AP1. Cotransfection with increasing doses of various AP4
constructs harboring deletions of LR1 and LR2, such as bHLH-V5,
PQ-V5, and dominant-negative AP4 (dnAP4), with a PAHX-AP1
promoter reporter did not repress luciferase activity in HEK293T
cells compared with cotransfection with WT AP4 or basic helix–
loop–helix LR-V5 (Fig. 2A). This result indicates that the LR-
containing Gem-binding domain of AP4 is important for the
transcriptional repressor activity of AP4 on the PAHX-AP1 pro-
moter. In HEK293T cells, cotransfection with increasing doses of
Gem with a PAHX-AP1 promoter reporter did not substantially
affect luciferase activity, whereas addition of AP4 (30 ng) dose-
dependently repressed luciferase activity (Fig. 2B). However, com-
pared with that in parent cells, repression of the PAHX-AP1
promoter by increasing doses of AP4 alone was not observed in
stably anti-sense Gem-transfected HEK293T cells that expressed
very low Gem levels (Fig. 2C Left). However, the addition of Gem
(30 ng) to the increasing doses of AP4 restored the dose-dependent
repression activity of AP4 on the PAHX-AP1 promoter (Fig. 2C
Right). These results indicate that AP4 and Gem work as transcrip-
tional repressor and corepressor, respectively, for the exogenous
PAHX-AP1 promoter.
To determine whether AP4 and Gem are necessary for the
transcriptional repression of PAHX-AP1 in vivo, we attempted to
overexpress them in primary neuronal cells. In cultured mouse
neuronal cells, transfection of AP4 alone, Gem alone, or both
weakly decreased the expression of PAHX-AP1 (Fig. 2D), which
indicates that AP4 and Gem also work as repressors for the
endogenous PAHX-AP1 promoter in neuronal cells. Collectively,
these data show that AP4 can form a specific, functional complex
with its partner Gem to repress the transcription of PAHX-AP1.
AP4 and Gem Work as a Functional Complex in Suppressing Neuronal
Gene Expression in Nonneuronal Cells. We next asked whether
suppression of AP4 or Gem derepresses target gene expression in
nonneuronal cells. We studied the activation of PAHX-AP1 ex-
pression in embryonic HEK293T cells that were stably transfected
with an anti-senseAP4 or anti-senseGem construct. The depressed
PAHX-AP1 expression in HEK293T cells was relieved by suppres-
sion of AP4 or Gem expression (Fig. 2E), indicating that AP4 and
Gem act as a transcription complex distinct from REST in sup-
pressing neuronal gene expression in nonneuronal cells.
Fig. 1. AP4 is a transcriptional repressor of the PAHX-AP1
promoter, and the C-terminal domain of Gem binds to the
leucine-repeat elements (LR1 and LR2) on AP4. (A) AP4 binds
to the PAHX-AP1 PRE, but Gem does not. (Left) Labeled PAHX-
AP1 PRE oligonucleotide was incubated with in vitro-
translated vector (lane 2), in vitro-translated AP4-V5 (lanes
3–7), or Gem (lane 8). Lane 1 is probe only. AP4-V5 was
incubated with probe alone (lane 3), excess cold probe (lanes
4 and 5), anti-V5 antibody (lane 6), or IgG (lane 7). The shifted
band due to AP4 binding with PRE (thin arrow) and the
supershifted band (thick arrow) are indicated. The dashed
arrow indicates nonspecific bands. (Right) Labeled WT (lanes
1 and 2) or mutant PAHX-AP1 PRE oligonucleotide (lanes 3 and
4) was incubated with AP4-V5 (lanes 2 and 4). (B) Interaction
of AP4 with Gem. HEK293T cells were immunoprecipitated
with anti-AP4 antibody and then blotted with anti-Gem an-
tibody (Upper) or reciprocally immunoprecipitated and
probed (Lower). Input is HEK293T cells. (C) ChIP assay showing
that AP4 and Gem bind to the AP4-binding site on the murine
PAHX-AP1 promoter. (D) Increasing doses of AP4 were tran-
siently cotransfected with WT PAHX-AP1 promoter reporter
(open bars) or AP4-binding site-mutated PAHX-AP1 promoter
reporter (filled bars) in HEK293T cells. After 48 h, cell extracts
were prepared and assayed for luciferase activity. Note that
the basal value of mutated PAHX-AP1 promoter reporter was
larger than that of WT PAHX-AP1 promoter reporter. Values
are mean SEM (n 3). (E) Various deletion constructs of AP4
were pulled down by whole Gem (Upper) or the C-terminal
domain of Gem (Lower) and analyzed by immunoblotting.
Input is in vitro-translated Gem. (F) HEK293T cells were tran-
siently transfected with various AP4 deletion constructs, including bHLH LR-V5, LR PQ-V5, PQ V5, and AP4 full-V5. V5 immunoprecipitation (IP) was performed,
and Gem was analyzed by immunoblotting. Input is HEK293T cells.
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AP4–Gem Complex Interacts with Corepressor SMRT. To explore
whether AP4 and Gem depend on other corepressors to recruit
or deacetylate proteins, we searched for Gem-interacting pro-
teins with the yeast one-to-one assay and found that the core-
pressor SMRT, but not mSin3 or N-CoR, partners with Gem
(Figs. 9C and 10A, which are published as supporting informa-
tion on the PNAS web site). Through in vitro pull-down assays,
we confirmed that SMRT binds to Gem but not to AP4 (Fig. 10
B and C). Thus, these results indicate that AP4–Gem complex
recruits SMRT.
AP4–Gem–SMRT Complex Recruits HDAC to Establish and Maintain
Trichostatin A (TSA)-Dependent Repression of Its Target Neuronal
Gene in Nonneuronal Cells. To demonstrate that an AP4–Gem–
SMRT complex recruits histone deacetylase 3 (HDAC3), which
interacts specifically with SMRT (16), we performed sequential
immunoprecipitation (IP). First, the AP4–Gem–SMRT complex
was immunoprecipitated in HEK293T cells with an anti-AP4
antibody and eluted away from the antibody. The eluant was
immunoprecipitated again with SMRT. Finally, the IP product was
probed for Gem (Fig. 3A) but not for HDAC3, because the size of
HDAC3 is 53 kDa, which overlaps with IgG. Instead, HDAC3
was immunoprecipitated in HEK293T cells and then probed sub-
sequently for AP4, Gem, and SMRT (Fig. 3B), indicating that the
AP4–Gem–SMRT complex binds to HDAC3. Next, we used a
GAL4-containing reporter construct to test whether functional
HDAC activity is involved in the AP4-Gem repressor system. A
synthetic GAL4-Gem construct was found to repress the target
gene activity of GAL4 luciferase in HEK293T cells with increasing
doses of Gem (Fig. 3C), and this repression was blocked by
pretreatment with 200 nM TSA, an HDAC inhibitor (17). More-
over, cotransfection of Gem with HDAC3 repressed reporter
activity more than transfection did with Gem alone (Fig. 3C, P 
0.05). We then assessed the expression of PAHX-AP1 in TSA-
pretreated HEK293T cells to investigate whether the target genes
of AP4–Gem become activated through blocking of histone
deacetylation. Maximal activation of PAHX-AP1 expression was
observed 12 h after treatment with 200 nM TSA (Fig. 3D), which
indicates that transcriptional repression of AP4–Gem target genes
in nonneuronal cells is relieved when HDAC activity is inhibited by
TSA, similar to NRSE-containing genes (2). Thus, our results
showed that AP4 and Gem recruit SMRT and HDAC3 and,
therefore, that histone deacetylation is essential for transcriptional
silencing via the AP4–Gem system. In contrast, REST represses
transcription by recruiting mSin3 and HDAC (17, 18). Transcrip-
tional repression via the recruitment of HDAC has been charac-
terized formany transcription factors, most of which recruit HDAC
by binding the corepressor mSin3 or NCorSMRT (19, 20).
Fig. 2. AP4–Gem complex works as a transcrip-
tional repressor of PAHX-AP1 expression. (A) Sche-
matic of the dominant-negative AP4 (dnAP4).
HEK293T cells were cotransfected with increasing
doses of wild-type AP4 or various AP4 deletion
constructs, including bHLH-V5, bHLH LR-V5, PQ-V5,
and dnAP4, and PAHX-AP1 promoter reporter.
(A–C)After48h, luciferaseactivitywasmeasuredas
in Fig. 1D. Values are mean  SEM (n  3). (B)
Increasing doses of Gem were transiently cotrans-
fected with (filled bars) or without (open bars) 30
ng of AP4 along with WT PAHX-AP1 promoter
reporter in HEK293T cells. (C Left) Stably anti-sense
Gem-transfected HEK293T cells express less Gem
than vector-transfected cells. (C Right) Increasing
doses of AP4 were transiently cotransfected with-
out or with Gem (30 ng) along with PAHX-AP1
promoter reporter in anti-sense Gem-transfected
cells. (D) Primary mouse neuronal cells were tran-
siently transfectedwithGemorAP4orboth10days
after seeding.After2days, totalRNAwasextracted
and PAHX-AP1 expression was examined by RT-
PCR. (E) Western blot analyses of PAHX-AP1 and
DYRK1A in HEK293T cells stably transfected with
anti-sense AP4 or anti-sense Gem construct.
Fig. 3. AP4–Gem–SMRT complex interacts with HDAC3 to
establish and maintain TSA-dependent repression of its target
gene in nonneuronal cells. (A) AP4–Gem–SMRT complex was
immunoprecipitated with anti-AP4 antibody in HEK293T cells,
eluted away from the antibody, and then immunoprecipi-
tated again with an anti-SMRT antibody. The final precipitate
was probed for Gem. (B) HDAC3 IP was performed in HEK293T
cells, and Gem, AP4, and SMRT subsequently were analyzed by
immunoblotting. (C) Increasing doses of Gem were transiently
cotransfected with synthetic GAL4-Gem construct in vehicle-
or TSA (200 nM)-pretreated HEK293T cells, and increasing
doses of HDAC3 were transiently cotransfected with or with-
out 30 ng of Gem along with synthetic GAL4-Gem construct in
HEK293T cells. Values are mean SEM (n 3). *, P 0.05. (D)
Time course for derepression of the PAHX-AP1 and DYRK1A
genes in HEK293T cells after exponentially proliferating cells
were incubated in the presence of TSA.
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AP4 and Gem Participate in the Developmental Expression of PAHX-
AP1 in the Brain. Because REST does not work as a transcriptional
repressor for PAHX-AP1, we investigated whether the brain-
specific temporal expression of PAHX-AP1 also is regulated by
AP4 and Gem. We examined in vivo expression patterns of AP4,
Gem, and PAHX-AP1 during brain development. Northern (Fig.
4A) andWestern blot (Fig. 4B) analyses showed that AP4 andGem
are widely expressed in most adult tissues but very weakly in an
adult brain. Also, AP4 and Gem exhibited similar patterns of
down-regulation during a temporal window from embryonic to
adult brain, in contrast with PAHX-AP1, which was developmen-
tally up-regulated during this window (Fig. 4C andD). To examine
whether theAP4–Gemcomplex has an in vivo regulatory role in the
developmental expression of target genes in brain, ChIP was
performed with an anti-AP4 or anti-Gem antibody at the PAHX-
AP1 promoter in brain tissues at several developmental time points.
We found a gradual reduction in AP4 and Gem occupancies at the
PAHX-AP1 promoter from the embryonic to adult brain (Fig. 4E).
This finding suggests that differences in availability of the AP4–
Gem complex during the developmental period may determine the
temporal expression of its target protein in the brain.
AP4 and Gem also Work as Transcriptional Repressors of Dual-
Specificity Tyrosine-Phosphorylated and Regulated Kinase 1A
(DYRK1A), a Candidate Gene for Down’s Syndrome (DS). We hypoth-
esized that abnormal expression of AP4 or Gem in fetal brain
causes premature overexpression of target genes and results in
neurologic disease. DYRK1A is a candidate gene for DS and is
overexpressed in a DS fetal brain (21). The DYRK1A gene
promoter has three potential AP4-binding sites. Moreover, the
C-terminal domain of DYRK1A interacts with PAHX-AP1, and
both genes have similar expression and distribution patterns in
brain. Also, PAHX-AP1 was reported to induce a relocalization of
DYRK1A from the nucleus to the cytoplasm, where PAHX-AP1
was localized and, thereby, may contribute to new cellular functions
of DYRK1A, suggesting possible involvement of the interaction of
PAHX-AP1withDYRK1A in the neurological pathogenesis of DS
(22). Therefore, we chose DYRK1A as a candidate target gene for
testing our AP4–Gem neurologic hypothesis that altered expres-
sion of AP4 and Gem in the fetal brain may result in neuropatho-
logic disease.
Binding of AP4–Gem to the three cis elements on the DYRK1A
promoter sequence was confirmed by ChIP in mouse and human
cells (Fig. 5A). Cotransfection of increasing doses of AP4 with
DYRK1A promoter luciferase decreased reporter activity dose-
dependently in HEK293T cells (Fig. 5B, left side). However,
deletion of two 5AP4 binding sites (33183313 and3263
3258) did not result in a loss of transcriptional repression in
response to AP4 (Fig. 5B, right side), which indicates that the
remaining 3 site (728723) is also working as a cis repressor
element. In addition, suppression of AP4 or Gem through an
anti-sense strategy resulted in elevated DYRK1A expression in
HEK293T cells (Fig. 2E), and DYRK1A expression is activated in
HEK293T cells after TSA treatment (Fig. 3D), just as for PAHX-
AP1. These data indicate that the AP4–Gem complex also works as
a transcriptional repressor of DYRK1A.
Decreased AP4 and Gem Expression and DYRK1A Overexpression in
the Cerebral Cortex of a DS Fetal Brain.Next, we examined the in vivo
expression patterns of AP4, Gem, PAHX-AP1, and DYRK1A in
healthy and DS fetal cortex at 20 weeks of gestational age by
immunohistochemistry. We found that the expression of AP4 and
Gem is markedly lower in the DS fetal cortex, especially Gem, than
in an age-matched healthy cortex, whereas the expression of
DYRK1A and PAHX-AP1 is higher (Fig. 5C). Also, DYRK1A
expression was developmentally up-regulated in mouse embryonic
brain from embryonic days 15 (E-15d) to E-20d, in contrast with
AP4 and Gem, which were developmentally down-regulated (Fig.
5D). These in vivo expression patterns indicate that down-
regulation ofAP4 andGem in theDS fetal brain correlates with the
premature overexpression of DYRK1A and suggest the reciprocal
regulation of DYRK1A expression in the DS fetal brain by the
AP4–Gem complex.
Restoring Gem Suppresses Reporter Expression in PAHX-AP1 Promoter-
LacZ TG Brain. Considering that primary neuronal cells have poor
transfection efficiency and are mixed with glial cells, which do not
Fig. 4. AP4 and Gem work as negative regulators of the
developmentalexpressionofPAHX-AP1inbrain. (AandB)Tissue
distribution of AP4, Gem, and PAHX-AP1 by Northern (A) and
Western(B)blotanalyses. (CandD)TemporalexpressionsofAP4,
Gem, and PAHX-AP1 in the mouse brain by Northern (C) and
Western (D) blot analyses. RNAs or proteins prepared from seven
different stages of brain development (embryonic, neonatal,
and adult) were used. For each RNA or protein blot, fidelity was
confirmed by reblotting with a GAPDH or actin probe. (E) ChIP
was performed with anti-AP4 and anti-Gem antibodies at PAHX-
AP1 promoter in brain tissue during several developmental time
points. Supernatant fluid from sonicated tissue of the corre-
sponding time point was divided into four aliquots. One aliquot
was the same protein amounts among each time point and was
used for ChIP assay (IgG, anti-AP4, or anti-Gem antibody) or
preparation of input DNA.
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express PAHX-AP1 (6), the repressive effects of AP4–Gem trans-
fer on endogenous PAHX-AP1 expression in neuronal cells are
relatively small (Fig. 2D). Thus, we tried gene delivery in TG mice
that express the lacZ reporter gene overdriven by exogenous
PAHX-AP1 promoter (10). In primary cultured neuronal cells
isolated from TG brain, which barely expresses endogenous Gem,
transfection of Gem modestly decreased the expression of -gal
mRNA (Fig. 5E). However, i.c.v. administration of the Gem
construct markedly repressed reporter expression but only weakly
suppressed endogenous PAHX-AP1 and DYRK1A in brain tissue
(Fig. 5E). This finding indicates that centrally administered Gem
efficiently suppressed the elevated transgene expression in the
brains of adult TG mice, which expressed little Gem just as in the
DS fetal brain (Figs. 4D and 5C). Considering that most neuronal
cells in the adult brain are postmitotic cells that have poor trans-
fection efficiency, our results suggest that delivery of Gem cDNA
into the lateral ventriclemay work in that compartment of neuronal
cells, which expressed reporter transgene driven by exogenous
PAHX-AP1 promoter, rather than in other neuronal cells driven by
endogenous PAHX-AP1 promoter.
Discussion
AP4 is a helix–loop–helix protein and dimerization through the
helix–loop–helix domain is a prerequisite for specific DNA binding
via a short region of basic residues (11). AP4 interacts with specific
sites in both promoter and enhancer regions of viral and cellular
enhancers (23), and mutation of these sites inactivates enhancer
activity and abolishes binding of AP4 in vitro (24). In this study, we
found that two leucine-repeat elements are important for binding
with the C-terminal domain of Gem and for repressor activity of
AP4, which indicates that interaction with Gem did not affect the
specific DNA-binding activity of AP4. Gem acts as a replication
licensing protein in the cell cycle (25), where it inhibits cycle
progression by sequestering Cdt1 (13), a key component for the
assembly of prereplication complex (26). Gem–Cdt1 interaction
blocks binding of the minichromosome maintenance complex to
origins of replication (13). Recently, Gem was reported to bind to
the transcription factors Hox (27) and Six3 (28), and this complex
controls cell proliferation by directly inhibiting the interaction of
Gem with Cdt1. In the present study, the interaction of Gem with
AP4 did not affect cell proliferation (data not shown); rather, AP4
acts cooperatively with Gem to restrict target neuronal gene
expression in nonneuronal cells by recruiting SMRT and HDAC at
the transcriptional level.
The mechanisms by which the developmental expression of
neuronal genes is regulated in the brain are not fully understood.
Zinc finger proteins are essential components of developmental
gene regulation and transcriptional activation. Modulation of zinc
finger proteins, such as Sp1 and zif268, has been shown to alter
developmental genes expression in the brain (29, 30). REST, also
a zinc finger protein, is widely expressed in nonneuronal tissues and
in neural precursors of the brain during fetal life (3, 4), and REST
mRNA levels decrease during rat brain development (31). This
report suggests that REST acts to prevent premature expression of
terminally differentiated genes in neural precursors and to repress
neuronal genes in nonneural tissues. Chen et al. (5) provided in vivo
genetic evidence thatREST is required to control the proper spatial
and temporal expression of neuronal genes. In this study, we found
that AP4 and Gem are widely expressed in most adult tissues, but
very weakly in adult brain, and that the temporal expression of
PAHX-AP1 in brain is increased as development progresses,
whereas that of AP4 and Gem gradually decreases. This result
suggests an inverse relation between the developmental expression
patterns of AP4–Gem and PAHX-AP1 in brain. Considering that
the AP4–Gem functional complex acts as a transcriptional repres-
sor of PAHX–AP1, which is not under regulation byREST (Fig. 7),
our results of a gradual reduction in occupancy of this complex at
the PAHX-AP1 promoter during the temporal window suggest that
AP4–Gem may work to regulate the developmental expression of
PAHX-AP1 in the brain.
REST-dependent neuronal III tubulin is derepressed in non-
neuronal cells ofREST/mice, whereas SCG10 and synapsin I are
not (5). This report indicates that complex mechanisms control
their neuron-specific expression andmay reflect differences in their
complement of cis-regulatory elements or in lacking positive trans-
acting factors needed in addition to relief from REST-imposed
silencing. The former explanation suggests the presence of addi-
tional cis-regulatory repressor elements that may determine dere-
Fig. 5. Expression of AP4 and Gem is decreased in cerebral cortex of the DS fetal
brain but DYRK1A is overexpressed. (A) ChIP assays showing that AP4–Gem binds
to the AP4-binding sites on murine and human DYRK1A promoter sequences.
DYRK1A-5 and DYRK1A-3 contain two 5 and one 3 AP4-binding site, respec-
tively. (B) Increasing doses of AP4 were transiently cotransfected with three
(3315, 3260, 725; left side) or one (725; right side) AP4 binding site-
containing DYRK1A promoter luciferase in HEK293T cells. Values are mean 
SEM (n  3). (C) Immunohistochemical analyses of AP4, Gem, DYRK1A, and
PAHX-AP1 expression in cerebral cortex of age-matched (20 weeks of gestation,
n  3) normal and DS fetal brain. The data show one of three representative
experiments. (Scale bar: 30m.) (D) Western blot analyses of expressions of AP4,
Gem, and DYRK1A in embryonic mouse brain. (E) Primary neuronal cells from
PAHX-AP1 promoter-LacZ TG brain were transiently transfected with Gem or
vector, and reporter expression was examined by RT-PCR (Upper). PAHX-AP1
promoter-LacZTGmiceweregiven i.c.v.GemoremptyvectormixedwithFuGENE
6. Five days after injection, proteins from whole brain were prepared and ana-
lyzed by immunoblotting (Lower). (F) Schematic of the transcriptional repression
of the target gene by AP4–Gem–SMRT complex in normal or DS fetal brain.
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pression when silencing by REST is relieved. Thus, we hypothesize
that the AP4 site may be an additional cis-repressor element that
may determine the derepression of neuronal genes in REST/
mice.
Identification of function of candidate genes and characterization
of their regulation are essential steps toward understanding the
complex neurodevelopmental abnormalities in DS. DYRK1A was
reported to be involved in the development of neurological deficits
in DS (21), but regulatory mechanisms in the fetal brain are not
understood. Impairment of REST and REST-dependent genes,
such as SCG10, in DS neuronal progenitor cells has been shown at
theRNA level (32), but REST-dependent proteins, such as SCG10,
synapsin I, and BDNF, were comparably expressed in the cortex of
DS and control fetal brains (33). Thus, the REST hypothesis of DS,
a positive link between dysregulation of REST and some of the
neurologic deficits seen in DS, has not been confirmed at the 18th
to 19th week of gestation (33). In this study, we found that
AP4–Gem represses the transcription of DYRK1A. Moreover,
expression ofAP4 andGem, especiallyGem, ismarkedly depressed
at 20 weeks of gestation in the DS fetal cortex, the major target
tissue in neurologic abnormalities in DS, which suggests that the
specific regulatory pathways of AP4–Gem in the DS fetal brain are
disrupted. Gem, one of the potential regulators of transcriptional
events during early neural development (12), is down-regulated
before neuronal differentiation and acts as a differentiation timer
controlling the transition from undifferentiated neural progenitors
to differentiated neurons by suppressing Brg1 and proneural basic
helix–loop–helix factors. In addition, reduced Gem expression was
reported to result in precocious neurogenesis in both Xenopus
embryos andP19 cells (34). Furthermore, we observed that delivery
of Gem into adult TG brain tissue markedly decreased the reporter
transgene expression, suggesting again that certain actions of Gem
are interrupted in theDS fetal brain because of marked depression.
Overall, our present results indicate that down-regulation of AP4
and Gem in the DS fetal brain correlates with the premature
overexpression of DYRK1A and suggest that the AP4–Gem com-
plex contributes to suppressing the inappropriate temporal expres-
sion of target genes in the fetal brain (Fig. 5F).
Materials and Methods
The investigation conformed to the Guide for the Care and Use of
Laboratory Animals published by the National Institutes of Health
(NIH publication no. 85-23, revised 1996). The Ethics Committee
of Chonnam National University Medical School and Chonnam
National University Hospital approved all experimental protocols.
Plasmids and Oligonucleotides. PAHX-AP1 reporter constructs
(-833-luciferase) were derived from a 5-kb fragment of the mouse
PAHX-AP1 promoter (10). CAGCTG was substituted for
GAATTC in the E box of the PAHX-AP1 promoter by PCR-based
site-directed mutagenesis. Various AP4 or Gem cDNAs were
obtained fromRT-PCR of mouse testis RNA and were cloned into
pcDNA3-V5-His mammalian expression vector (Invitrogen, Carls-
bad, CA). A mammalian expression vector for Gal4 fusion to Gem
was constructed by inserting the appropriate Gem fragment into
pCMXGal4N. The Gal4-tk-luc reporter plasmid contains five
tandem repeats of GAL4-binding sites, followed by herpes simplex
virus-thymidine kinaseminimal promoter. A series of corepressors,
SMRT(a gift fromRonaldM.Evans, The Salk Institute, SanDiego,
CA), mSin3A, and N-CoR, were constructed by inserting appro-
priate fragments into pcDNA3.1-V5-His plasmid (Invitrogen). Hu-
man and murine DYRK1A promoters (5-kb) were obtained by
PCR of genomic DNA.
Immunohistochemistry. Three human fetal brain tissue specimens
fromDS fetuses and three age-matched fetal brain tissue specimens
from spontaneously aborted fetuses (20 weeks of gestation) were
obstetrically obtained through therapeutic abortion at Chonnam
University Hospital (Kwangju, Korea) and used for immunohisto-
chemistry. The brain was excised and immersed in a 4% parafor-
maldehyde fixative overnight at 4°C. The tissue blocks werewashed,
dehydrated, embedded in paraffin, cut into 6-m sections, and
mounted. Immunohistochemistry was performed by using an im-
munoperoxidase procedure as described in ref. 10. The sections
were incubated for 12 h with antibodies to AP4 (Chemicon,
Temecula, CA), Gem (Santa Cruz Biotechnology, Santa Cruz,
CA), PAHX-AP1 (6), and DYRK1A (a gift from W. J. Song, Inje
University, Daejeon, Korea) diluted in PBS with 0.3% BSA.
Supporting Information.Additional details can be found in Support-
ing Methods, which is published as supporting information on the
PNAS web site.
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